<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01675219</url>
  </required_header>
  <id_info>
    <org_study_id>FinnBladder 9</org_study_id>
    <secondary_id>2012-000559-15</secondary_id>
    <nct_id>NCT01675219</nct_id>
  </id_info>
  <brief_title>Fluorescence Cystoscopy and Optimized MMC in Recurrent Bladder Cancer (FinnBladder 9)</brief_title>
  <official_title>Treatment of Ta Bladder Cancer in High Risk of Recurrence - Fluorescence Cystoscopy With Optimized Adjuvant Mitomycin-C (FinnBladder 9)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Finnbladder</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Turku University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bladder cancer (BC), the second most common urological malignancy, is an important public
      health issue. One of the main challenges in the treatment of bladder cancer if the prevention
      of recurrences of non-invasive tumors, which is also associated with significant costs.

      The current study will investigate optimal treatment of patients with bladder cancer with
      high risk of tumor recurrence but low risk of progression. The main interest is comparison of
      photodynamic (PDD) bladder tumor resection (TUR-BR)to traditional TUR-BT. Also the efficacy
      of adjuvant optimized mitomycin-C is compared to patients with no adjuvant treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>bladder cancer recurrence rate</measure>
    <time_frame>2 years</time_frame>
    <description>any bladder cancer recurrence at 2 years.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bladder cancer progression</measure>
    <time_frame>2 years</time_frame>
    <description>bladder cancer progression to T2 or higher</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment failure</measure>
    <time_frame>2 years</time_frame>
    <description>progression, recurrence or side effects preventing completing the trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>2 years</time_frame>
    <description>death due bladder cancer or other reasons</description>
  </secondary_outcome>
  <other_outcome>
    <measure>costs</measure>
    <time_frame>2 years</time_frame>
    <description>For analysis of cost-effectiveness. All bladder cancer treatment and treatment complications related costs are included.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blue light TUR-BT with no adjuvant instillations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>White light TUR-BT with no adjuvant instillations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>White light TUR-BT with six weekly optimized mitomycin-C instillations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blue light (PDD) TUR-BT with six weekly optimized mitomycin-C instillations.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>white light TUR-BT</intervention_name>
    <description>traditional transurethral bladder tumor resection</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>blue light TUR-BT</intervention_name>
    <description>photodynamic transurethral bladder tumor resection</description>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>optimized MMC</intervention_name>
    <description>six weekly optimized mitomycin-C instillations</description>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
    <other_name>optimized mitomycin-C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>single immediate chemotherapy instillation</intervention_name>
    <description>single immediate post TUR-BT epirubicin (2mg/ml, total of 100 ml) instillation</description>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
    <other_name>single instillation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Primary papillary bladder cancer at high risk for further recurrence as defined as
        follows:

        Number of primary tumors ≥2, OR Size of solitary primary tumor ≥ 3 cm, OR Recurrent
        papillary tumors

          -  Histologically proven Ta bladder cancer

          -  Histological grade 1-2 (WHO 1973 grading system) or papillary urothelial neoplasm of
             low malignant potential (PUNLMP) or low grade (WHO 2004 grading system) bladder cancer

          -  Written informed consent is required from every eligible patient

        Exclusion Criteria:

          -  Grade 3 tumors (WHO 1973 grading system), or high grade tumors (WHO 2004 grading
             system)

          -  CIS (carcinoma in situ)

          -  Suspicion or evidence of papillary tumors or CIS of the upper urinary tract

          -  Non-TCC (transitional cell carcinoma, i.e. urothelial carcinoma) bladder cancer

          -  Suspicion or previous history of the patient not tolerating intravesical instillations

          -  Known allergy to MMC or hexaminolevulinate (HAL, Hexvix®)

          -  Urethral stricture, stone disease, chronic urinary tract infection or any other
             urological condition that may compromise study participation (as judged by treating
             physician)

          -  Pregnancy or lactating patient

          -  Other non-cured malignancy (excepting skin basalioma or cancer in situ of the cervix
             uteri or any other malignancy in remission ≥5 years)

          -  Age &lt; 18 years

          -  Expected survival time less than one year

          -  Expected poor compliance (e.g. some severe psychiatric disorders, antisocial
             behaviour, or dementia)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter J. Boström, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Turku University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eero Kaasinen, Md, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hyvinkää District Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter J Boström, MD, PhD</last_name>
    <phone>+358 2 313035925</phone>
    <email>peter.bostrom@tyks.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Riikka Järvinen, MD</last_name>
    <phone>+358 50 427 1015</phone>
    <email>riikka.järvinen@hus.fi</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>HYKS Peijas Hospital</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Riikka Järvinen, MD</last_name>
      <phone>+358 50 4271015</phone>
    </contact>
    <investigator>
      <last_name>Riikka Järvinen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hyvinkää District Hospital</name>
      <address>
        <city>Hyvinkää</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eero Kaasinen, MD</last_name>
      <email>eero.kaasinen@hus.fi</email>
    </contact>
    <investigator>
      <last_name>Eero Kaasinen, Md, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kuopio University Hospital</name>
      <address>
        <city>Kuopio</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sirpa Aaltonen, MD</last_name>
      <email>sirpa.aaltonen@kuh.fi</email>
    </contact>
    <investigator>
      <last_name>Aaltomaa Sirpa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mikkeli Central Hospital</name>
      <address>
        <city>Mikkeli</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tapani Liukkonen, MD</last_name>
      <email>tapani.liukkonen@esshp.fi</email>
    </contact>
    <investigator>
      <last_name>Tapanki Liukkonen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oulu University Hospital</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markku Vaarala, MD</last_name>
      <email>markku.vaarala@ppshp.fi</email>
    </contact>
    <investigator>
      <last_name>Markku Vaarala, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Satakunnan keskussairaala</name>
      <address>
        <city>Pori</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marjo Seppänen, MD</last_name>
      <email>marjo.seppanen@satshp.fi</email>
    </contact>
    <investigator>
      <last_name>Marjo Seppänen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seinäjoki Central Hospital</name>
      <address>
        <city>Seinäjoki</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Timo Marttila, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hatanpään sairaala</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tarmo Pekkarinen, MD</last_name>
      <email>tarmo.pekkarinen@pshp.fi</email>
    </contact>
    <investigator>
      <last_name>Tarmo Pekkarinen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juha Koskimäki, MD</last_name>
      <email>juha.koskimaki@pshp.fi</email>
    </contact>
    <investigator>
      <last_name>Juha Koskimäki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Peter J. Boström, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2012</study_first_submitted>
  <study_first_submitted_qc>August 28, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2012</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Turku University Hospital</investigator_affiliation>
    <investigator_full_name>Peter Boström</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>bladder cancer</keyword>
  <keyword>recurrence</keyword>
  <keyword>photodynamic diagnosis</keyword>
  <keyword>PDD</keyword>
  <keyword>cost analysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

